← Leaderboards
Vincent Lo Re
University Of Pennsylvania
$11,285,101
Attributed
$14,113,162
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,110,903 · 8
AHRQ$2,495,701 · 1
By mechanism
R01$8,976,265 · 3
T32$3,128,488 · 1
P60$1,493,442 · 1
P30$758,362 · 1
K01$665,145 · 1
R21$453,821 · 1
Top collaborators
- Amy Caroline Justice6 shared
- Sean P Hennessy5 shared
- Julie A Womack1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Felix W Wehrli$41,563,685
- Katharine June Bar$15,418,177
- Ian Frank$25,757,892
- Michael Joseph Povelones$2,242,374
- Megan Povelones$229,874
Others in their field
Top investigators on “Training”
- Jeffrey P Krischer · University Of South Florida$314,856,919
- Christopher McKay · Battelle Memorial Institute$290,340,771
- Judith S. Currier · University Of California Los Angeles$276,624,848
- Daniel R Kuritzkes · Brigham And Women'S Hospital$258,658,543
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$239,830,683
- Steven E Reis · University Of Pittsburgh At Pittsburgh$232,330,444
Research focus
TrainingHepatitis C VirusPersonsCohort StudiesHepatitis CAgingEpidemiologyObesityCohortResponseMorbidity - Disease RateChronicIncidenceRisk FactorsMortalityInsightAlcohol ConsumptionMediatingHiv/HcvFutureBaseVeteransClinical PracticeInflammation
Grant awards (32)
Aging Well with HIV through Alcohol Research and Risk Reduction and Education (AWAR3E) Center$1,493,442
P60 · FY2025 · AA
Clinical Pharmacoepidemiology Training Grant$661,172
T32 · FY2025 · GM
Clinical Core$375,756
P30 · FY2025 · AI · contact PI
Clinical Pharmacoepidemiology Training Grant$663,867
T32 · FY2024 · GM
Clinical Core$382,606
P30 · FY2024 · AI · contact PI
Clinical Pharmacoepidemiology Training Grant$625,020
T32 · FY2023 · GM
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy$776,106
R01 · FY2022 · AI · contact PI
Clinical Pharmacoepidemiology Training Grant$610,802
T32 · FY2022 · GM
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy$777,720
R01 · FY2021 · AI · contact PI
Clinical Pharmacoepidemiology Training Grant$567,627
T32 · FY2021 · GM
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy$790,034
R01 · FY2020 · AI · contact PI
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer$470,334
R01 · FY2020 · CA
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy$794,282
R01 · FY2019 · AI · contact PI
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer$454,026
R01 · FY2019 · CA
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy$814,787
R01 · FY2018 · AI · contact PI
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer$512,833
R01 · FY2018 · CA
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer$527,068
R01 · FY2017 · CA
Risk of Liver Complications with HBV and HIV Viremia During Tenofovir-Based ART$244,615
R21 · FY2017 · AI · contact PI
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer$563,374
R01 · FY2016 · CA
Risk of Liver Complications with HBV and HIV Viremia During Tenofovir-Based ART$209,206
R21 · FY2016 · AI · contact PI
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications$498,425
R01 · FY2014 · HS · contact PI
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications$498,792
R01 · FY2013 · HS · contact PI
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications$499,975
R01 · FY2012 · HS · contact PI
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications$499,729
R01 · FY2011 · HS · contact PI
Risk factors and prediction of liver disease in HIV/HCV$133,029
K01 · FY2011 · AI · contact PI
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications$498,780
R01 · FY2010 · HS · contact PI
Risk factors and prediction of liver disease in HIV/HCV$133,029
K01 · FY2010 · AI · contact PI
Risk factors and prediction of liver disease in HIV/HCV$133,029
K01 · FY2009 · AI · contact PI
Risk factors and prediction of liver disease in HIV/HCV$133,029
K01 · FY2008 · AI · contact PI
Risk factors and prediction of liver disease in HIV/HCV$133,029
K01 · FY2007 · AI · contact PI
Weight Loss During Treatment of Hepatitis C in HIV$61,822
F32 · FY2005 · DK
Weight Loss During Treatment of Hepatitis C in HIV$69,259
F32 · FY2004 · DK